Cover Image
Market Research Report

Global Endometriosis Drug Market- Size, Trends, Competitive Analysis, Market Share and Forecasts (2018-2025)

Published by DataM Intelligence Product code 755500
Published Content info 130-180 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Endometriosis Drug Market- Size, Trends, Competitive Analysis, Market Share and Forecasts (2018-2025)
Published: March 1, 2018 Content info: 130-180 Pages
Description

Global Endometriosis Market (2018-2025)

The global endometriosis market is estimated to reach a market value of USD 1807.78 million by 2017 and the market is estimated to grow at a CAGR of 2.52% in the forecasted period 2018-2025. The global endometriosis market is estimated to reach a market value of USD XX million by 2025. Endometriosis is a painful disorder in which tissue that normally lines the inside of your uterus leading pelvic pain and infertility.

It is estimated that around 10% of the women across the world are suffering with endometriosis. Around 176 million people are suffering with endometriosis worldwide and is the second most gynecological problem. It takes an average of 7.5 years to detect the problem, with no definite cure for the endometriosis and the infertility rate as high as 30-50%.

Increased awareness about the disease, increased adoption of oral contraceptive pill, and increasing incidents of endometriosis due to improved diagnostics techniques are some of the major factors driving the growth of the market. Ineffective drugs therapies, poor success rate are the major factors restraining the growth of the market.

Europe accounts for the largest number of clinical trials by region with France accounting for most number of clinical trials in Europe. By country, United States account for the largest number of clinical trials. By therapy type, Hormone therapy account for more than 75% of the market share with rest being accounted by the pain medications. By Distribution channel, pharmacies account for the largest market share in 2017 with its market share getting reduced by 2025 due to growing e-commerce sector. E-commerce sector accounts for a considerable market share in 2025.

The market is segmented into:

Drug Class

Gonadotropins Releasing Hormone agonists

Progestin

Non-Steroidal Anti-Inflammatory drugs

Oral contraceptive pills

Therapy Type

Pain Management

Hormonal Therapy

Some of the major companies in global endometriosis market include

Pfizer

Bayer

Eli Lilly

Astrazeneca

The endometriosis market is a fragmented market with top 5 companies accounting for only 40% of the market share. Partnerships and acquisitions are the key strategies followed by the major companies in the industry

Some of the recent industry developments include

Pfizer has received US FDA approval for Depo-Provera for treatment of endometriosis

AbbVie has received U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain

Why purchase the report?

Visualize the composition of the endometriosis market across each indication, in terms of type and applications, highlighting the key commercial assets and players.

Identify commercial opportunities in endometriosis market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of the endometriosis market - level 4/5 segmentation

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study

Product mapping in excel for the key endometriosis market products of all major market players

Target Audience

Raw Material Suppliers/ Buyers

Product Suppliers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

Table of Contents

1 Methodology and Scope

  • 1.1 Research methodology
  • 1.2 Scope of the Report

2. Headlines & Trends

  • 2.1 Headlines
  • 2.2 Key Trends & Developments

3. Industry Analysis

  • 3.1 Market Drivers
  • 3.2 Market Restraints
  • 3.3 Porters Five Forces Analysis
    • 3.3.1 Suppliers Power
    • 3.3.2 Buyer Power
    • 3.3.3 Industry Competition
    • 3.3.4 Threat of new Entrant
    • 3.3.5 Threat of Substitutes

4. Clinical Trial Analysis

  • 4.1 By Age Group
    • 4.1.1 Child
    • 4.1.2 Adult
    • 4.1.3 Senior
  • 4.2 By Study Phases
    • 4.2.1 Early Phase
    • 4.2.2 Phase 1
    • 4.2.3 Phase 2
    • 4.2.4 Phase 3
    • 4.2.5 Phase 4
  • 4.3 By Study Type
    • 4.3.1 Interventional
    • 4.3.2 Observational

5. Product Pipeline Analysis

6. Segmentation by Drug Class

  • 6.1 Gonadotropins Releasing Hormone agonists
  • 6.2 Progestin
  • 6.3 Non-Steroidal Anti-Inflammatory drugs
  • 6.4 Oral contraceptive pills

7. Segmentation by Route of Administration

  • 7.1 Oral
  • 7.2 Nasal Spray
  • 7.3 Intrauterine Systems
  • 7.4 Parenteral

8. Segmentation by Therapy Type

  • 8.1 Pain Management
  • 8.2 Hormonal Therapy

9. Segmentation by Distribution Channel

  • 9.1 Pharmacies
  • 9.2 E-Commerce
  • 9.3 Others

10. Geographic Analysis

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
    • 10.1.4 Others
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Spain
    • 10.2.3 Germany
    • 10.2.4 France
    • 10.2.5 Italy
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 India
    • 10.3.2 China
    • 10.3.3 Australia
    • 10.3.4 Japan
    • 10.3.5 Rest of Asia-Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Rest of South America
  • 10.5 Rest of the World

11. Competitive Landscape

  • 11.1 Market Share Analysis
  • 11.2 Company Benchmarking
  • 11.3 Key Strategies Adopted by Major Companies

12. Company Profiles*

  • 12.1 AbbVie Inc
  • 12.2 Neurocrine Biosciences
  • 12.3 Pfizer
  • 12.4 Bayer
  • 12.5 Eli Lilly
  • 12.6 Takeda Pharmaceutical
  • 12.7 Meditrina Pharmaceuticals
  • 12.8 ObsEva
  • 12.9 AstraZeneca
  • 12.10 Astellas Pharma

13. Appendix

  • 13.1 Sources
  • 13.2 List of Charts
  • 13.3 Expert Panel Validation
  • 13.4 Disclaimer
  • 13.5 Contact Us
Back to Top